Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Raeeka Khamari"'
Autor:
Anne Trinh, Raeeka Khamari, Quentin Fovez, François-Xavier Mahon, Béatrice Turcq, Didier Bouscary, Patrice Maboudou, Marie Joncquel, Valérie Coiteux, Nicolas Germain, William Laine, Salim Dekiouk, Sandrine Jean-Pierre, Veronique Maguer-Satta, Bart Ghesquiere, Thierry Idziorek, Bruno Quesnel, Jerome Kluza, Philippe Marchetti
Publikováno v:
Molecular Metabolism, Vol 55, Iss , Pp 101410- (2022)
Objective: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, eviden
Externí odkaz:
https://doaj.org/article/bffd69c235194487adfbf1e0576e3453
Autor:
Patrice Maboudou, Véronique Maguer-Satta, Bruno Quesnel, Quentin Fovez, Raeeka Khamari, William Laine, Jérôme Kluza, Sandrine Jeanpierre, Didier Bouscary, Béatrice Turcq, Philippe Marchetti, Salim Dekiouk, Anne Trinh, Marie Joncquel, Thierry Idziorek, Valérie Coiteux, Bart Ghesquière, Nicolas Germain, Francois-Xavier Mahon
Publikováno v:
Molecular metabolism
Molecular metabolism, 2022, 55, pp.101410. ⟨10.1016/j.molmet.2021.101410⟩
Molecular Metabolism, Vol 55, Iss, Pp 101410-(2022)
Molecular Metabolism
Molecular metabolism, 2022, 55, pp.101410. ⟨10.1016/j.molmet.2021.101410⟩
Molecular Metabolism, Vol 55, Iss, Pp 101410-(2022)
Molecular Metabolism
OBJECTIVE: Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective cure for chronic myeloid leukemia (CML) patients and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, eviden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90935945bd9dd8f0e6793149b698bc1c
https://hal.science/hal-03086546v2/file/1-s2.0-S2212877821002684-main.pdf
https://hal.science/hal-03086546v2/file/1-s2.0-S2212877821002684-main.pdf
Autor:
Bruno Quesnel, Béatrice Turcq, Didier Bouscary, Raeeka Khamari, Salim Dekiouk, Jerome Kluza, Nicolas Germain, Francois-Xavier Mahon, Quentin Fovez, Patrice Maboudou, William Laine, Valérie Coiteux, Philippe Marchetti, Marie Joncquel, Thierry Idziorek, Bart Ghesquière, Anne Trinh
Long-term treatment with tyrosine kinase inhibitors (TKI) represents an effective treatment for chronic myeloid leukemia (CML) and discontinuation of TKI therapy is now proposed to patient with deep molecular responses. However, evidence demonstratin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5925202479711cc8a5629bc5150cc0bf
https://doi.org/10.1101/2020.09.21.305714
https://doi.org/10.1101/2020.09.21.305714
Publikováno v:
FASEB journal : official publication of the Federation of American Societies for Experimental BiologyREFERENCES. 34(10)
Mitochondrial metabolism must constantly adapt to stress conditions in order to maintain bioenergetic levels related to cellular functions. This absence of proper adaptation can be seen in a wide array of conditions, including cancer. Metabolic adapt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bf6290926f0b2db5f2e6b7746b023ba
https://pubmed.ncbi.nlm.nih.gov/32808332
https://pubmed.ncbi.nlm.nih.gov/32808332
Publikováno v:
Biochimica et Biophysica Acta (BBA) - General Subjects. 1862:999-1005
Background Besides its influence on survival, growth, proliferation, invasion and metastasis, cancer cell metabolism also greatly influences the cellular responses to molecular-targeted therapies. Scope of the review To review the recent advances in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a4428f3816107d8dc6997d69bfe48eb
https://doi.org/10.1016/j.bbagen.2018.01.018
https://doi.org/10.1016/j.bbagen.2018.01.018
Autor:
Raeeka Khamari, William Laine, Quentin Fovez, Nicolas Germain, Jérôme Kluza, Céline Berthon, Philippe Marchetti, Claude Preudhomme, Laure Goursaud, Bruno Quesnel
Publikováno v:
Blood. 136:7-7
Introduction The persistence of leukemic cells after treatment limits the effectiveness of anticancer drugs and is the cause of relapse in patients with acute myeloid leukemia (AML). After exposure to chemotherapeutic drugs, the survival of leukemic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::389bcf319a8c56d2e2932b2b3f787f02
https://doi.org/10.1182/blood-2020-139510
https://doi.org/10.1182/blood-2020-139510
Autor:
Anne Trinh, Philippe Marchetti, Bruno Quesnel, Quentin Fovez, Raeeka Khamari, William Laine, Jérôme Kluza
Publikováno v:
Blood. 136:31-31
Introduction Acute myeloid leukemias are a group of malignant hemopathies characterized by a poor prognosis for survival. The discovery of oncogenic mutations in the FLT3 gene (eq FLT3-ITD) has led to the development of new tyrosine kinase inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f79ccbbe1343043f1d34689f5038de3
https://doi.org/10.1182/blood-2020-139696
https://doi.org/10.1182/blood-2020-139696
Autor:
Jerome Kluza, M. Joncquel, A. Trinh, Philippe Marchetti, S. Dekiouk, Raeeka Khamari, William Laine, Bruno Quesnel, V. Coiteux, Thierry Idziorek
Publikováno v:
ESMO Open. 3:A123-A124
Introduction Tyrosine kinase inhibitors (TKI) have dramatically changed the prognosis of patients with leukaemia. Unfortunately, they fail to achieve durable remissions for many patients with advanced BCR-Abl leukaemia or acute myelogenous leukaemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73b55e557bbb67a4738f2ae554c82119
https://doi.org/10.1136/esmoopen-2018-eacr25.296
https://doi.org/10.1136/esmoopen-2018-eacr25.296